Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Loss of mismatched HLA in leukemia after stem-cell transplantation.

Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MT, Perrelli NF, Cosentino C, Torri F, Angius A, Forno B, Casucci M, Bernardi M, Peccatori J, Corti C, Bondanza A, Ferrari M, Rossini S, Roncarolo MG, Bordignon C, Bonini C, Ciceri F, Fleischhauer K.

N Engl J Med. 2009 Jul 30;361(5):478-88. doi: 10.1056/NEJMoa0811036.

2.

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW.

Cancer. 2009 Aug 15;115(16):3670-9. doi: 10.1002/cncr.24429.

3.

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.

Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D.

Cancer Res. 2009 May 1;69(9):4010-7. doi: 10.1158/0008-5472.CAN-08-3712. Epub 2009 Apr 21.

4.

Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting.

Capitini CM, Cooper LJ, Egeler RM, Handgretinger R, Locatelli F, Sondel PM, Mackall CL.

J Pediatr Hematol Oncol. 2009 Apr;31(4):227-44. doi: 10.1097/MPH.0b013e31819a5d8d.

5.

Myeloid-derived suppressor cells: linking inflammation and cancer.

Ostrand-Rosenberg S, Sinha P.

J Immunol. 2009 Apr 15;182(8):4499-506. doi: 10.4049/jimmunol.0802740. Review.

6.

The promise and potential pitfalls of chimeric antigen receptors.

Sadelain M, Brentjens R, Rivière I.

Curr Opin Immunol. 2009 Apr;21(2):215-23. doi: 10.1016/j.coi.2009.02.009. Epub 2009 Mar 25. Review.

7.

The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management.

Movva S, Verschraegen C.

Expert Opin Biol Ther. 2009 Feb;9(2):231-41. doi: 10.1517/14712590802643347 . Review.

PMID:
19236253
8.

Harnessing invariant NKT cells in vaccination strategies.

Cerundolo V, Silk JD, Masri SH, Salio M.

Nat Rev Immunol. 2009 Jan;9(1):28-38. doi: 10.1038/nri2451. Review.

PMID:
19079136
9.

Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.

Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A; ALL-REZ BFM Study Group.

J Clin Oncol. 2009 Jan 20;27(3):377-84. doi: 10.1200/JCO.2008.17.6065. Epub 2008 Dec 8.

PMID:
19064980
10.

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.

Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK.

Nat Med. 2008 Nov;14(11):1264-70. doi: 10.1038/nm.1882. Epub 2008 Nov 2.

11.

Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens.

Arrenberg P, Halder R, Kumar V.

J Cell Physiol. 2009 Feb;218(2):246-50. doi: 10.1002/jcp.21597. Review.

12.

Progress in the curative treatment of childhood hematologic malignancies.

Wayne AS, Reaman GH, Helman LJ.

J Natl Cancer Inst. 2008 Sep 17;100(18):1271-3. doi: 10.1093/jnci/djn306. Epub 2008 Sep 9. No abstract available.

PMID:
18780861
13.
14.

Interleukin-21: biology and application to cancer therapy.

Andorsky DJ, Timmerman JM.

Expert Opin Biol Ther. 2008 Sep;8(9):1295-307. doi: 10.1517/14712598.8.9.1295 . Review.

PMID:
18694350
15.

A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.

Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M, Kopp W, Tsokos M, Berzofsky JA, Helman LJ.

Clin Cancer Res. 2008 Aug 1;14(15):4850-8. doi: 10.1158/1078-0432.CCR-07-4065.

16.

Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.

Sportès C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, Fleisher TA, Krumlauf MC, Babb RR, Chow CK, Fry TJ, Engels J, Buffet R, Morre M, Amato RJ, Venzon DJ, Korngold R, Pecora A, Gress RE, Mackall CL.

J Exp Med. 2008 Jul 7;205(7):1701-14. doi: 10.1084/jem.20071681. Epub 2008 Jun 23.

17.

Cancer immunology.

Finn OJ.

N Engl J Med. 2008 Jun 19;358(25):2704-15. doi: 10.1056/NEJMra072739. Review. No abstract available.

PMID:
18565863
18.

Successful outcome of allo-SCT in high-risk pediatric AML using chemotherapy-only conditioning and post transplant immunotherapy.

Bonanomi S, Connor P, Webb D, Ancliff P, Amrolia P, Rao K, McCloskey D, Hemmatpour S, Goulden N, Veys P.

Bone Marrow Transplant. 2008 Aug;42(4):253-7. doi: 10.1038/bmt.2008.160. Epub 2008 Jun 16. Erratum in: Bone Marrow Transplant. 2008 Nov;42(9):635. Bonnanomi, S [corrected to Bonanomi, S].

PMID:
18560412
19.

Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease.

Brichard VG, Lejeune D.

Expert Opin Biol Ther. 2008 Jul;8(7):951-68. doi: 10.1517/14712598.8.7.951 . Review.

PMID:
18549325
20.

Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Aplenc R, Alonzo TA, Gerbing RB, Lange BJ, Hurwitz CA, Wells RJ, Bernstein I, Buckley P, Krimmel K, Smith FO, Sievers EL, Arceci RJ; Children's Oncology Group.

J Clin Oncol. 2008 May 10;26(14):2390-3295. doi: 10.1200/JCO.2007.13.0096.

Supplemental Content

Support Center